<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101271248</journal-id>
<journal-id journal-id-type="pubmed-jr-id">36076</journal-id>
<journal-id journal-id-type="nlm-ta">Expert Rev Clin Immunol</journal-id>
<journal-id journal-id-type="iso-abbrev">Expert Rev Clin Immunol</journal-id>
<journal-title-group>
<journal-title>Expert review of clinical immunology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1744-666X</issn>
<issn pub-type="epub">1744-8409</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30884251</article-id>
<article-id pub-id-type="pmc">7003574</article-id>
<article-id pub-id-type="doi">10.1080/1744666X.2019.1596800</article-id>
<article-id pub-id-type="manuscript">NIHMS1035568</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Recent advances in our understanding of mast cell activation – or should it be mast cell mediator disorders?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Theoharides</surname>
<given-names>Theoharis C.</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="aff" rid="A3">c</xref>
<xref ref-type="aff" rid="A4">d</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tsilioni</surname>
<given-names>Irene</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ren</surname>
<given-names>Huali</given-names>
</name>
<xref ref-type="aff" rid="A5">e</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>a</label>Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Immunology, Tufts University School of Medicine, Boston, MA, USA</aff>
<aff id="A2"><label>b</label>Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA</aff>
<aff id="A3"><label>c</label>Department of Internal Medicine, Tufts University School of Medicine and Tufts Medical Center, Boston, MA, USA</aff>
<aff id="A4"><label>d</label>Department of Psychiatry, Tufts University School of Medicine and Tufts Medical Center, Boston, MA, USA</aff>
<aff id="A5"><label>e</label>Department of Otolaryngology, Beijing Electric Power Hospital, Beijing, China</aff>
<author-notes>
<corresp id="CR1">CONTACT Theoharis C. Theoharides <email>theoharis.theoharides@tufts.edu</email> MD Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Immunology, Tufts University School of Medicine, 136 Harrison Avenue Boston, MA, 02111, USA
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>8</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>22</day>
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>06</day>
<month>2</month>
<year>2020</year>
</pub-date>
<volume>15</volume>
<issue>6</issue>
<fpage>639</fpage>
<lpage>656</lpage>
<!--elocation-id from pubmed: 10.1080/1744666X.2019.1596800-->
<abstract id="ABS1">
<sec id="S1">
<title>Introduction:</title>
<p id="P1">An increasing number of patients present with multiple symptoms affecting many organs including the brain due to multiple mediators released by mast cells. These unique tissue immune cells are critical for allergic reactions triggered by immunoglobulin E (IgE), but are also stimulated (not activated) by immune, drug, environmental, food, infectious, and stress triggers, leading to secretion of multiple mediators often without histamine and tryptase. The presentation, diagnosis, and management of the spectrum of mast cell disorders are very confusing. As a result, specialists have recently excluded neuropsychiatric symptoms, and made the diagnostic criteria stricter, at the expense of excluding most patients.</p>
</sec>
<sec id="S2">
<title>Areas covered:</title>
<p id="P2">A literature search was performed on papers published between January 1990 and November 2018 using MEDLINE. Terms used were activation, antihistamines, atopy, autism, brain fog, heparin, KIT mutation, IgE, inflammation, IL-6, IL-31, IL-37, luteolin, mast cells, mastocytosis, mediators, myalgic encephalomyelitis/chronic fatigue syndrome, mycotoxins, release, secretion, tetramethoxyluteolin, and tryptase.</p>
</sec>
<sec id="S3">
<title>Expert opinion:</title>
<p id="P3">Conditions associated with elevated serum or urine levels of any mast cell mediator, in the absence of any comorbidity that could otherwise explain such increases, should be considered mast cell activation disorders, or better yet be collectively termed ‘Mast Cell Mediator Disorders (MCMD).’ Emphasis should be placed on the identification of unique mast cell mediators, and development of drugs or supplements that inhibit their release.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Activation</kwd>
<kwd>antihistamines</kwd>
<kwd>autism spectrum disorder</kwd>
<kwd>brain fog</kwd>
<kwd>KIT mutation</kwd>
<kwd>cytokines</kwd>
<kwd>IgE</kwd>
<kwd>inflammation</kwd>
<kwd>IL-6</kwd>
<kwd>IL-37</kwd>
<kwd>luteolin</kwd>
<kwd>mast cells</kwd>
<kwd>mastocytosis</kwd>
<kwd>mediators</kwd>
<kwd>myalgic encephalomyelitis/chronic fatigue syndrome</kwd>
<kwd>mycotoxins</kwd>
<kwd>tetramethoxyluteolin</kwd>
<kwd>tryptase</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>